Skip to content
OpenCapital
Get started

Atara Biotherapeutics ATRA Q4 2025 Annual earnings

Reported March 16, 2026 · Before market open

Revenue$1.6MMiss by $1.7M
EPS-$0.25Miss by $0.16
Revenue estimate$3.4M
EPS estimate-$0.09

Next report

Aug 10, 2026 (In 1 week)
Revenue estimate$550.0K
EPS estimate-$0.32

Versus estimates

Revenue

Q1 2026$516.0KMiss by $2.4M
Q4 2025$1.6MMiss by $1.7M
Q3 2025$3.5MBeat by $2.8MQ2 2025$17.6MBeat by $15.8MQ1 2025$98.1MBeat by $93.8MQ4 2024$32.8MBeat by $12.2M

Diluted EPS

Q1 2026-$0.29Beat by $0.04
Q4 2025-$0.25Miss by $0.16
Q3 2025-$0.32Beat by $0.51Q2 2025$0.19Beat by $0.51Q1 2025$3.50Beat by $6.57Q4 2024-$1.19Beat by $2.63

Ask the moment Atara Biotherapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Atara Biotherapeutics report Q4 2025 earnings?
Atara Biotherapeutics (ATRA) reported Q4 2025 earnings on March 16, 2026 before market open.
What were Atara Biotherapeutics's Q4 2025 revenue and EPS?
Atara Biotherapeutics reported revenue of $1.6M and eps of $-0.25 for Q4 2025.
Did Atara Biotherapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $3.4M by $1.7M. EPS missed the consensus estimate of $-0.09 by $0.16.
How did Atara Biotherapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 95.0% from $32.8M a year earlier and eps grew 79.0% from $-1.19.
Where can I find Atara Biotherapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-108344) and the 10-K periodic report (0001193125-26-108361) directly on SEC EDGAR. The filing index links above go to sec.gov.